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Abstract.  22 CHO  sFv (BFY) cell lines were isolated 
at a  frequency 2-30  x  10  -7 from mutagenized popula- 
tions on the basis of their ability to grow in the pres- 
ence of 1 #g/ml brefeldin A  (BFA). Four of the five 
mutant lines tested are genetically stable and none of 
the mutant lines characterized degrade this drug.  Im- 
munofluorescence studies reveal that whereas early en- 
dosomes and the Golgi complex have nearly identical 
BFA sensitivities in the parent CHO line, the relative 
sensitivities of these two organelles were dramatically 
altered in all six mutant lines tested. Four cell lines 
maintain  normal Golgi appearance at a BFA concen- 
tration as high as  10 #g/ml.  Mutant lines show wide 
variation in the level of resistance to growth inhibition 
by BFA, but none of the mutant lines characterized 
grow above 2 #g/ml BFA. This specific growth inhibi- 
tion is observed under conditions where Golgi mor- 
phology and function remain unaffected, suggesting 
that some factor(s) unrelated to Golgi function re- 
mains sensitive to BFA in BFY mutant lines.  These 
observations provide strong evidence for the presence 
of multiple,  organdie-specific targets for BFA. Cell- 
free measurements with membrane extracts establish 
that resistance to BFA in BFY-1 cells involves a 
membrane-associated factor distinct from ARFs and 
coatomers. This collection of mutant lines may prove 
valuable for the identification of intracellular  target(s) 
for BFA and/or of effectors that interact upstream or 
downstream with these targets, thereby uncovering the 
cascade which regulates assembly of organelle-specific 
coats. 
REFELDIN A  (BFA)  1 is  a  lipophilic  fungal  metabo- 
lite  that  blocks  protein  secretion  (Misumi  et  al., 
1986) and induces rapid and profound morphological 
changes in several organelles  of the secretory pathway (re- 
iewed in Pelham,  1991; Klausner et al., 1992). Remarkably, 
these effects are completely reversible  (Donaldson et al., 
1990).  These properties make BFA a unique and powerful 
tool to unravel the mechanisms  that underly organelle struc- 
ture and identity. 
In many different  cell types, BFA causes disassembly of 
the Golgi complex and redistribution of Golgi resident en- 
zymes into the ER (reviewed in Klausner et al., 1992). This 
transformation  prevents  normal transport of proteins from 
the  ER and  results  in  a  block of protein  secretion.  The 
resorption of Golgi cisternae into the endoplasmic reticulum 
occurs by extension of tubules which subsequently fuse with 
the ER, a process greatly enhanced by microtubules (Lippin- 
cott et al.,  1990).  Although  it is often assumed that BFA 
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transfi~rrin; Man  II,  mannosidase  II;  VSV, vesicular  stomatitis  virus; 
VSV-G, envelope glycoprotein of VSV. 
causes the complete disappearance of the Golgi complex, the 
presence of vesicle clusters and tubules containing  Golgi 
markers,  or Golgi "remnants; has been documented in sev- 
eral cell lines  (Ulmer and Palade,  1991; Hendricks et al., 
1992; Hidalgo et al., 1992). The reorganization  of the Golgi 
complex caused by BFA can be detected as a dramatic de- 
crease in the rate of processing of carbohydrate side chains 
which normally occurs as glycoproteins transit  through the 
individual  cisternae of the Golgi (Klausner et al., 1992 and 
references  therein). 
The effects of BFA are not limited to the Golgi complex. 
Treatment  with BFA causes extensive tubulation and fusion 
of the early endosome (EE) and the TGN to form a hybrid 
organdie  (TGN/EE),  clustering  in  the  form  of tubulo- 
vesicular elements  near the microtubule-organizing  center 
(Lippincott et al., 1991; Tooze and Hollinshead, 1992; Wood 
and Brown,  1992).  Limited tubulation of lysosomes also 
results from BFA treatment in some cell types (Lippincott  et 
al.,  1991; Wood et ai.,  1991), but these tubular lysosomes 
remain separate from the TGN/EE hybrid. These morpho- 
logical  transformations  appear to have no significant  effect 
on the ability of cells to recycle transferrin  and extract iron 
(Lippincott et al.,  1991). Transfer  of material  from EE to 
lysosomes also continues in most cell types in spite of these 
morphological changes  (Wood et al.,  1991). 
Several lines of evidence suggest that the effects of BFA on 
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target protein. First, closely related structural analogues of 
BFA  are  completely  inactive,  including  7-epi-  and  4,7- 
diacetyl-10-epoxy-derivatives of BFA  (Orci  et  al.,  1991; 
Donaldson et al., 1992; Klausner et al., 1992). Second, BFA 
treatment of a heterokaryon resulting from the fusion of a 
BFA-sensitive  cell (CV-1) with a  naturally occurring BFA- 
resistant cell (PtK1) does not affect the Golgi originating 
from the resistant variant while completely disassembling 
the Golgi from the  sensitive cell (Ktistakis et al.,  1991). 
These observations strongly suggest that the target for BFA 
is a protein, and that it is most likely membrane associated. 
A signifcant step towards understanding the mechanism 
of action of BFA was made when it was established that BFA 
interferes  with  assembly  of cytoplasmic  coats  on  Golgi 
membranes.  Two main coat protein complexes have been 
characterized in detail, the classic clathrin coat found on 
coated endocytic pits on the cytoplasmic face of the TGN, 
and a distinct nonclathrin coat observed on vesicles associ- 
ated with the Golgi complex (Melan~on et al., 1991; Klaus- 
ner et al.,  1992;  Rothman and Orci,  1992).  BFA has been 
shown to prevent association of B-COP-containing coatomer 
with Golgi membranes both in vivo and in vitro (Donaldson 
et al., 1991a, b). Interference with coat assembly may be a 
general mechanism to explain the effects of BFA on all mem- 
brane systems. Indeed, BFA has also been shown to prevent 
assembly of  clathrin-coated vesicles driven by Golgi-localized 
adaptor complexes (Robinson and Kreis,  1992). 
Recent evidence suggests that the effect of BFA on coat as- 
sembly may be, in part, a consequence of interfering with 
the association of ADP-ribosylation factor (ARF) with the 
Golgi membranes.  ARFs are small GTPases required for 
both the assembly of coat proteins  on Golgi membranes 
(Donaldson et al., 1991a, 1992; Palmer et al., 1993) and the 
formation of transport vesicles on Golgi cisternae (Taylor et 
al.,  1994).  The exchange of GTP for GDP on ARFs pro- 
motes its membrane association (Kahn, 1991) and BFA was 
found to interfere with this nucleotide exchange activity in 
vitro on recombinant ARF (Donaldson et al., 1992; Helms 
and Rothman, 1992; Randazzo et al., 1993).  However, this 
effect  may be indirect. Members of  the heterotrimeric G-pro- 
tein family appear to be also involved in coat assembly, pos- 
sibly by regulating guanine nucleotide exchange on ARFs 
(Bomsel and Mosto,  1992;  Melan~on,  1993).  It has been 
shown that pretreatment with agents that activate G-proteins 
specifically (i.e., without effects on ARFs or other members 
of the ras superfamily), such as aluminum fluoride and bac- 
terial toxins, can prevent the effect of BFA on the association 
of/S-COP with Golgi membranes (Donaldson et al.,  1992; 
Ktistakis et al., 1992).  These observations may suggest that 
G-proteins or their activators are the true cellular target(s) 
of BFA. 
Comparison with various cell lines derived from a variety 
of tissues  and  species  (Pelham,  1991) showed that BFA 
affects many cell lines in an organelle-specific manner. For 
example, whereas BFA blocks protein exit from ER-Golgi 
systems in most cell lines, it has no such effect in MDCK 
(Hunziker et al., 1991) or PtK1 cells (Ktistakis et al., 1991). 
Also, an apparent block in transport to lysosomes reported 
in chick embryo fibroblasts (Lippincott et al.,  1991) is not 
observed in either NRK cells, bovine testicular cells (Wood 
and Brown, 1992), or rat hepatocytes (Misumi et al., 1986). 
These observations, although suggestive,  do not establish 
that the organelle-specific effects of BFA result from interac- 
tion of BFA with distinct, organelle-specific, targets. For ex- 
ample, different  organelle-specific  effects between various cell 
lines could be obtained if the activity of a unique BFA target 
were required to different extents by the various endomem- 
brahe systems in a species- or tissue-dependent manner. 
In this study, 22 CHO  B}w mutant lines were isolated on 
the basis of their ability to grow in the presence of BFA. We 
find that whereas early endosomes and the Golgi complex 
have nearly identical BFA sensitivities in the parent CHO 
line, the relative sensitivities of these two organdies were 
dramatically altered in all mutant lines tested. This observa- 
tion suggests that the organelle-specific effects by BFA in our 
mutant lines are unlikely to arise from the differential re- 
quirement of the activity of a unique BFA target in different 
organdies and thus provides strong evidence for the pres- 
ence of multiple cellular targets for BFA. Cell-free measure- 
ments with membrane extracts establish that resistance to 
BFA in BFY-1 cells involves a membrane-associated factor 
distinct from ARFs and coatomers and therefore suggest that 
resistance in these cells could have occurred by mutation of 
the BFA target itself. The availability of these CHO  sFv mu- 
tant lines derived from a single parent line and demonstrat- 
ing organelle-specific BFA resistance will provide important 
tools to identify and characterize the multiple molecular in- 
teractions leading to assembly of organelle-specific protein 
coats. 
Materials and Methods 
Reagents 
BFA was purchased from either Epicentre Technologies (Madison, WI) or 
Sigma Chemical Co. (St. Louis, MO), and was stored at -20°C as a stock 
solution of 5 mg/ml in either 100% ethanol or DMSO. BFA analogues, B27 
and B36, were generous gifts from Dr. J. Donaldson CNIH, Bethesda, MD) 
and were stored at -20°C in DMSO.  Endoglycosidase  H (endo-H), ATE 
UTP, creatine phosphate, rabbit creatine phosphokinase, and iron-saturated 
human transferrin were purchased from Boehringer Mannheim Biochemi- 
cals (Indianapolis,  IN). Unless otherwise indicated, all other biochemicals 
were obtained from Sigma Chemical Co. 
Antibodies 
The  m3A5  mouse  monoclonai antibody  which  recognizes  the  ll0-kD 
/S-COP protein was generously supplied by Dr. Thomas Kreis (University of 
Geneva,  Switzerland).  A rabbit antiserum raised against Golgi mannosi- 
dase II (Man ID was kindly provided by Drs. K. Moremen (University of 
Georgia,  Athens, GA)  and M.  Farquhar (University  of California-San 
Diego, LaJolla,  CA). Rabbit anti-human transferrin antibody, rhodamine- 
and FITC-labeled goat anti-mouse, and goat anti-rabbit IgG were obtained 
from Boehringer Mannheim Biochemicals and used at 1:400 for antibody 
to  transferrin and  1:200  dilution for fluorophore-labeled  antibodies.  A 
mouse monoclonal antibody against the envelope glycoprotein  of vesicular 
stomatitis virus (VSV-G) was prepared by chromatography over protein-A 
Sepharose (Pharmacia LKB Biotechnology  Inc., Piscataway, NJ) of super- 
natant of cultures of hybridoma clone 8G5 (LeFrancois et al.,  1982),  a 
generous gift of Dr.  LeFrancois (Upjohn Company,  Kalamazoo,  MI). 
Cell Culture, Cytosol, and Golgi-enriched 
Membrane Preparation 
The parent line for our studies,  CHO  pr°-5 (American Type Culture Collec- 
tion, Rockville, MD), is a derivative of line CHO-S, a cell line adapted for 
growth in Suspension culture.  The terms CHOpro-~ and wild-type CHO 
will be used interchangeably  in this paper.  CHO  pr°-~ and Clio  sw mutant 
lines were maintained in ct-MEM supplemented with 7.5 % fetal calf serum, 
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virus 0/b-T), Indiana strain, was propagated in BI-IK  cells and stored as cul- 
ture superuatant  in small aliquots at  -700C. Golgi-enriched membranes 
and cytosol were prepared from crude homogenates of CHO cells as de- 
scribed (Balch et al.,  1984). 
EMS Mutagenesis of CHO~-5 (V~ld 1)~e) Cell  Line 
CHO  pr°-5 cells were plated in cc-MEM medium supplemented with 7.5% 
fetal bovine serum at a concentration of 2  x  106 cells/150-mm petri dish. 
After 6 h, cells were treated with 300 #g/ml of  ethyl methanesulfonate (Al- 
drich Chemical Co., Milwaukee, WI) for 16 h to a survival level of 75%. 
Thymidine at a concentration of  2 #g/mi was included to increase mutagen- 
esis efficiency (Peterson et al., 1978). Cells were then cultured for a total 
of 3 d before challenge with 1 #g/mi of  BFA. Colonies which appeared 1-2 
wk after BFA treatment were cloned and cultured in the presence of 0.5 
/~g/mi BFA for several days before freezing and storage in liquid N2. 
Cell Growth  Assay 
The cell growth assay was modified from the method of Bodary (Bodary 
et ai., 1989). Cells from either wild-type or mutant lines were plated in 96- 
well tissue culture plates (6-8  x  103 cells per well) and treated with con- 
centrations of  BFA from 0 to 2.0 ~g/mi. After 48 h of  culture (enough time 
for control wells to reach near conflueney), the plates were washed with 
PBS and fixed in 10% formaldehyde for 30 rain. Each well was then treated 
with 0.5% crystal violet in 20% methanol for 10 rain (Bodary et al., 1989) 
and washed three times with ddH20 to remove free dye. Bound dye was 
released from the cells with 50 ~,1 1% SDS in distilled water. The absor- 
bance at 595 nm was determined using an ELISA plate reader (Vmax; Mo- 
lecular Devices, Menlo Park, CA). Control experiments established that the 
absorbance at 595 am is proportional to the number of  ceils present in each 
well. Each assay was done in triplicate,  and repeated four or more times. 
Labeling of Early Endosomes and 
Immunofluorescence Microscopy 
CHO cells were grown on coverslips (No.l). Early endosomes were labeled 
by incubating cells first with BSA (5 mg/ml) in a-MEM for 30 rain, and 
then with 10 #g/ml of  iron-saturated human transferrin (hi'f) for 1 h at 370C 
as described  (Lippincott-Schwarz et al., 1991). After the various treatments 
indicated in the text,  cells grown on coverslips were washed briefly with 
PBS, fixed with 3.7 % formaldehyde in PBS for 10 min at room temperature 
and then permeabilized with 0.1% TX-100 and 0.05% SDS in PBS for less 
than 4 min. After several washes with PBS, cells were incubated with pri- 
mary antibody in PBS for 45 min to 1 h, washed, and incubated for 45 rain 
to 1 h with rhodamine- or FITC-conjugated secondary antibodies. After a 
brief rinse with water, the cells were mounted and viewed on a microscope 
equipped  for epifluorescence  (M35;  Karl Zeiss,  Oberkochen,  Germany) 
(Fig. 6) or for confocal microscopy (MultiProbe 2001; Molecular Dynamic 
Corp,  Sunnyvale, CA) (see Fig. 5). 
Thin Layer Chromatography of l~I-I]BFA 
7-[3H]BFA (3.2 Ci/mmol; a generous gift of Dr. E Wieland, University of 
Heidelberg, Germany) was added to 100 #1 suspensions (final BFA concen- 
tration '~0.3 #g/ml) containing 1 ×  106 cells of either the wild type or var- 
ious mutant lines in c~-MEM supplemented with 10 mM Hepes (pH 7.4). 
Following a 5-h incubation at 37°C, the cells were then separated from incu- 
bation medium by centrifugation and the cell pellets were extracted with 20 
~1 methanol/water (1:1). 5-#1 aliquots of  the incubation medium and cell ex- 
tract were subjected to thin layer chromatography on silica gel 60 plates (E. 
Merck,  Darmstadt,  Germany).  The TLCs  were developed using one of 
two different mobile phases: chloroform/methanol (80:20), or chloroform/ 
methanol/water/formic acid (10:10:3:0.6) which yield Re values for BFA of 
0.5 and 0.9, respectively. TLC plates were treated with Amplify (Amersham 
Corp., Arlington Heights, IL) as per manufacturer's instructions, dried, and 
exposed to x-ray autoradiographlc film for fluorography. The fluorograms 
were quantitated by densitometry (ULTRO-SCan  laser densitometer; LKB, 
Uppsala, Sweden). Quantitation demonstrated that the fraction of BFA as- 
sociated with the cell pellet was consistantly small (,o10%) in wild type and 
in all BFY lines tested, whether measured after a short (1 h) or long (5 h) 
incubation. 
Analysis of VSV-G Glycoprotein Processing 
Subconfluent monolayers of mutant  BFY-1 or wild-type  CHOP  r°-5 cells 
growing in six-well culture plates were infected with VSV for 2 h 45 min, 
washed free of  unbound virus, and then incubated for 30 rain in the presence 
or absence of  2 #g/mi BFA in DME medium free of  methionine. Cells were 
then pulse labeled for 15 min with 20 t~Ci/well of [35S]methionine (Trans- 
35S-label; ICN Bioehemicals, Inc., Irvine, CA) at 37"C. At the end of the 
pulse,  the radioactive medium was removed and the cells were chased in 
complete medium containing a 104 molar excess of cold methionine for 0 
or 60 rain, in the absence or presence of  2 #g/rul BFA. The chase was termi- 
nated by placing the cells on ice. Cells were then lysed with 0.25 ml lysis 
buffer (50 mM Tris  [pH 7.5],  1%  Triton  X-100, 1%  DOC,  and  1 mM 
EDTA). Nuclei were removed by cold centrifugation for 10 min. VSV-G  an- 
tibody was then incubated with 100-#1 samples for 1 h on ice followed by 
incubation with protein-A Sepharose 4B fast flow (Sigma Chemical Co.) 
(1:1) in lysis buffer. The precipitates  were  recovered by  centrifugation, 
washed three times with cold lysis buffer, resuspended in 20 ~1 of 0.8% 
/~-mereaptoethanol and 0.1% SDS in 0.1 M sodium acetate (pH 5.5), and 
heated for 5 rain at 95"C. Samples were then divided into two equal ali- 
quots. For endo-H digestion, one aliquot was incubated with one milliunit 
of endo-H per 30-td reaction volume for 16 h at 37°C. The digestion was 
terminated with addition of Laemmli sample buffer. Samples were heated 
at 90"C for 5 rain before loading onto  10% SDS-gel. 
Quantitation of  ARFs, ~-COR and Binding of 
Coatomers to Golgi Membranes 
The relative amounts of ARFs and E-COP in cellular extracts were deter- 
mined using GTP-ligand blots and immunoblots, respectively. For ARF de- 
tection, GTP-ligand blots were used since they are significantly more sensi- 
tive than immunoblots. GTP-ligand blots of  total cellular extracts, cytosol, 
and Golgi-enriched membrane fractions were carried out essentially as de- 
scribed fl~,lor et al., 1994) and quantitated using a Phosphorlrnager (Mo- 
lecular  Dynamics  Corp.).  For determination  of E-COP levels, proteins 
transferred to nitrocellulose were probed with monoclonal antibody m3A5 
and detected by enhanced chemiluminescence (ECL; Amersharn Corp., Ar- 
lington Heights, IL). The results were quantitated by demitometry (ULTRO- 
Scan laser densitometer;  LKB). Membrane association of coatomers was 
measured using a/~-COP binding assay which contained 90 #g of cytosol 
prepared either from BFA-sensitive  CHO cells and 10 #g of Golgi-enriched 
membranes  prepared  either  from BFA-sensitive CHO  'r°-5 cells or from 
mutant BFY-1 cells in a final volume of 200 ~1. The assay was carried out 
in a buffer containing 25 mM Hepes (7.4), 50 mM KCI, 2.5 mM MgC12 
and an ATP-regenerating system (8 U/mi creatine phosphokinase, 5 mM 
creatine phosphate,  100 #M ATE and 100 #M GTP).  Following a 20-rain 
incubation in the presence  or absence of  BFA at 300C, membranes were col- 
lected by centrifugation and resuspended in SDS sample buffer. All of each 
sample was loaded on 10% SDS gel and the relative amounts of  membrane- 
associated/~-COP  quantitated by Western blot as described above. 
Results 
Selection of  BFA-resistant CHO Cell Lines 
Preliminary studies with the parent cell line CHOp  ~5 (here- 
after referred to as wild type) showed that BFA at concentra- 
tions as low as 0.2 #g/ml inhibited growth of wild-type CHO 
cells.  Addition of the drug to cells grown  in monolayers 
caused the ceils to round up within 12 h and to completely 
detach from the substratum after 48 h of continuous expo- 
sure. This demonstrated the feasibility of selecting resistant 
cell lines by addition of drug to the growth medium. 
BFA-resistant colonies were selected by challenging ethyl 
methanesulfonate (EMS)-mutagenized CHO monolayers with 
1 #g/ml BFA. Resistant colonies appeared after 1-2 wk of 
continuous growth. Three such selections  yielded  22 indi- 
vidual cell lines at frequencies varying from 2-30 colonies 
per  107 mutagenized cells (Table I).  These cell lines were 
labeled BFY-1 to BFY-22. The frequency at which these mu- 
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to Brefeldin A 
Time for colony  Frequency 
Mutant cell lines  appearance  mutants/107  cells 
BFY-1  to BFY-3  1 wk  2-4 
BFY-4 to BFY-6  2  wk  =30 
BFY-7 to BFY-22  2  wk  15 
CHO  p~-5 cells were treated with 300/~g/ml EMS to a survival level of 75%. 
Cells were then cullm'ed  in the absence  of EMS for 3 d before replating in medium 
containing 1 #g/ml of BFA, as described  in Materials  and Methods. Three separate 
selections were carried out. The time and frequency at which colonies appeared 
in each case are listed. 
tam lines were obtained suggests that although there might 
be multiple targets for BFA, mutation in a  single gene is 
sufficient to allow growth under our selection conditions. 
Recent reports on the isolation of a mutant Vero and two mu- 
tant human carcinoma lines which can grow in the presence 
of BFA support this interpretation (Chen et al.,  1992;  Se- 
guchi et al.,  1992). 
Cell Lines Vary Greatly in the Level of  Resistance 
to BFA 
The mutant cell lines were first characterized with respect 
to their resistance to growth inhibition in the presence of 
BFA. A  growth assay was performed as described in Ma- 
terials and Methods.  Using this assay,  the growth proper- 
ties of wild type and 10 randomly chosen mutant lines were 
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Figure 1.  The growth of mutant cHo aFY cell lines display varied 
and distinct extents of resistance to BFA.  Equivalent amounts of 
cells from each cell line to be tested (6-8  ×  103 cells/well) were 
delivered to each well in a  96-well tissue culture plate. BFA was 
administered at increasing concentrations from 0 to 2.0/~g/ml and 
added fight after plating. As controls, one well was left untreated 
while another received an appropriate amount of DMSO, the sol- 
vent used to dissolve BFA. The number of cells remaining attached 
after 48 h  was evaluated using the cell growth assay described in 
Materials  and  Methods.  BFA-sensitive wild-type  CHOm-S  cells 
were used as a control in each experiment. Each line was tested in 
triplicates and the results ate expressed as fraction of maximum cell 
growth relative to the OD595 measured for cells grown in the ab- 
sence of BFA. Four to five such titrations were carried out for each 
cell line and the average values with error (standard deviation) were 
plotted in a  semi-log scale. 
Table II.  Results of Growth Assays on Subset of the 
BFY Mutant Lines 
LD~* 
Mutant line  ~g/ml 
Pro-5  0.2 
BFY-I 1  0.4 
BFY-21  0.5 
BFY-15  0.8 
BFY-16  0.8 
BFY-9  1.3 
BFY-1  1.6 
BFY-2  1.6 
BFY-3  1.7 
BFY-7  1.7 
BFY-12  >1.0 
* Lethal dose 50%. Growth assays at several BFA concentrations were carded 
out for each cell line as described in legend to Fig. 1. The concentration of BFA 
which causes a 50% reduction in cell density after 48-h incubation, or LD~o, 
is listed for each cell line tested. 
compared. The doubling times for growth of all mutant lines 
in the absence of BFA are very similar and nearly identical 
to that of the parent line. The effect of BFA on the growth 
of a subset of these lines is shown in Fig. 1. The concentra- 
tions of  BFA required to cause a 50% decrease in cell density 
(LDs0) after two days of culture were determined for each 
cell line based on at least four separate titrations with BFA 
and are given in Table II. These results demonstrate that mu- 
tant cell lines are indeed resistant to BFA compared to the 
parent wild-type line. Furthermore, we find that BFY mutant 
lines vary greatly with respect to their tolerance for BFA in 
the growth assay. Differences in the mechanism of resistance 
among the mutant lines could account for this variation. 
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Figure 2.  Growth inhibition by BFA observed in mutant lines is 
specific. Wild-type and the mutant BFY-I cell lines were used for 
a cell growth assay as described for Fig.  1. Increasing mounts of 
either BFA or its analogue, 7-¢pi-BFA (B27) were added to succes- 
sive wells. The extant of growth measured after 48 h  is plotted as 
a function of drug concentration. Treatment with the analogue B27 
(solid lines) has no growth inhibition on both wild-type and BFY-I 
mutant lines. Similar results were obtained with another inactive 
analogue, 4,7-diacetyl-lO-epoxy-BFA (B36)  (data not shown). 
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Figure 3. The BFA resistance phenotype is genetically stable• Mu- 
tant BFY-7 and BFY-9 grown for different lengths of time in absence 
of BFA were used for cell growth assays similar to those presented 
in Fig.  1. The duration of culture in absence of BFA is indicated. 
Growth Inhibition by BFA Observed in Mutant Lines 
Is Specific 
Despite the fact that mutant lines are clearly resistant to BFA 
relative to wild-type CHO cells,  growth  inhibition  is  ob- 
served at BFA concentrations above 1 #g/ml in all mutant 
lines tested and none of the mutant lines grow at BFA con- 
centrations above 2  #g/ml (Fig.  1).  To determine whether 
this growth inhibition at high BFA concentration results from 
nonspecific  effects,  several  BFA  inactive  analogues  were 
tested in the cell growth assay. As shown in Fig. 2, a 7-epimer 
of BFA, also called B27, had no effect in this assay either on 
wild-type or on mutant BFY-1 cells at concentrations as high 
as 3.0 #g/ml. Similar results were obtained (data not shown) 
with another BFA analogue, 4,7-diacetyl-10-epoxy-BFA, or 
B36, which has also been shown to be inactive in displacing 
B-COP  from  Golgi  membranes  0.  Donaldson,  personal 
communication). 
The BFA-resistant Phenotype Is Genetically Stable in 
Most Lines Tested 
The stability of the phenotype was tested by comparing the 
growth properties of several lines following prolonged cul- 
ture in the absence of the drug.  If resistance results from a 
stable  genetic  change  (as  opposed  to  transient  gene  am- 
plification),  we would expect the LDso for a  given line to 
remain  unaffected  by  extensive  culture  in  the  absence of 
drug.  The results obtained with two cell lines, BFY-7 and 
BFY-9,  grown in the absence of BFA for less than two or 
greater than 24 wk are shown in Fig. 3. Clearly, culture for 
up to 26 wk in the absence of BFA caused no reduction in 
the level of resistance. Similar results were obtained for the 
BFY-1  and BFY-12  lines. 
Resistance to BFA Does Not Result  from 
Drug Degradation 
Previous studies by E  Wieland and colleagues on the stabil- 
ity of BFA in CHO cells have established that BFA can be 
metabolically deactivated,  primarily via conjugation  with 
Figure  4. Resistance to BFA in 
mutant cell lines tested is not 
due  to  BFA  degradation  or 
modification  of the  drug  by 
mutant  cells.  CHO~-5  cells 
and  mutant  cells  were  in- 
cubated  with  [3H]BFA  in 
c~-MEM containing  10  mM 
Hepes (pH 7.4) to give final 
concentration  of  0.3  /~g/ml 
[3H]BFA.  Samples  a-f cor- 
respond  to  wild  type,  and 
BFY-1,  -7,  -11,  -12,  -21, 
respectively. Following a 5-h 
incubation,  the  cells  were 
separated  from  medium  by 
centrifugation.  Small aliquots 
of  medium and cell pellet (dis- 
solved in 50% methanol) were 
subjected to TLC as described 
in  Materials  and  Methods. 
The solvent used for this experiment was optimized to resolve BFA with an Rf value of 0.5. Fluorograms  of the TLC plates are shown 
and arrows indicate the position of the origin and solvent front. A fivefold greater amount of cell pellet material (right) relative to medium 
(left) was loaded and the TLC for the pellet fractions was exposed to film three times longer. Fluorngrams were quantitated by densitometry. 
A threefold increase in exposure did not lead to detection of any other spots. Quantitation demonstrated that the fraction of BFA associated 
with the cell pellet was consistantly  small (,~10%) in wild type and in all BFY lines tested, whether measured after a short (1 h) or long 
(5 h) incubation. 
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whether degradation is enhanced in BFY mutants, and estab- 
lished that no significant degradation of BFA is observed in 
all five of the mutant lines tested. 
The metabolism of 7-[3H]BFA in either wild type or vari- 
ous mutant lines was investigated as described in Materials 
and Methods. The results of thin layer chromatography anal- 
ysis of medium and cell extracts prepared after a 5-h incuba- 
tion  with  7-pH]BFA  are  presented  in  Fig.  4.  No  BFA 
degradation products were observed in any of the cell lines 
tested,  either in the cell pellet or in the medium.  Similar 
results were obtained using another solvent system with a 
very different Re value (data not shown).  The lack of sig- 
nificant degradation or modification of BFA observed here 
is inconsistent with the slow (36 ng h-~/l@ cells) modifica- 
tion of BFA previously reported (Briining et al., 1992). This 
difference could result from the use of different CHO isolates 
in the two studies. Resistance to BFA might also have arisen 
from lack of import or increased export of the drug. These 
possibilities are eliminated by experiments presented below 
in Fig.  6. 
The Morphology of the Golgi Complex in Mutant Cells 
Is Stable to BFA 
The effect of BFA on the Golgi complex of mutant lines with 
Figure 5. The Golgi morphol- 
ogy in CHO  ~m mutant  lines 
is resistant  to different levels 
of BFA. Wild-type (A and B), 
BFY-1 (C-E), BFY-7 (F-H), 
and BFY-9 if-K)  CHO cells 
were incubated in the absence 
and presence  of various con- 
centrations of BFA for 1 h and 
then  washed.  After  fixation 
and permeabilization, the cells 
were  incubated  sequentially 
with a polyclonal antibody spe- 
cific for Man lI and a goat anti- 
rabbit IgG conjugated  with rho- 
damine or F1TC. The concen- 
tration of BFA used is given in 
the bottom left comer in units 
of ~g/ml.  The distribution  of 
Man II is unaffected by BFA 
at 1/~g/ml in all mutant lines 
tested and at concentrations as 
high  as  20  /~g/ml in  BFY-1 
cells. 
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CHO  aev mutant lines tested. Early endosomes were labeled by in- 
cubating cells first with BSA (5 mg/ml) in ot-MEM for 30 rain, and 
then with 10 #g/ml of  iron-saturated hTf for 1 h at 37°C. Cells were 
treated in the absence or presence (1 gg/ml) of BFA for 30 min at 
37°C, followed by fixation with formaldehyde and permeabilization 
for immunofluorescence with a rabbit antibody to hTf and FITC- 
labeled goat anti-rabbit IgG. BFA causes redistribution of the early 
endosomes to a perinuclear  location in all cells tested.  A similar 
result  was obtained  even when  using  a lower concentration  (0.2 
#g/rul) of BFA. 
the highest level of resistance to BFA was investigated by in- 
direct immunofluorescence using an antibody to Man II, a 
Golgi marker. The results, presented in Fig. 5, demonstrate 
that while wild-type ceils showed dispersed reticular stain- 
ing in the presence of 0.2 #g/ml BFA, the appearance of the 
Golgi complex of BFY-1,  -7,  and  -9  was  not  significantly 
changed at  1 gg/ml BFA. 
However, at concentrations of BFA greater than 1/zg/ml, 
the Golgi morphology of mutant lines tested displayed differ- 
ent levels of resistance to BFA.  Furthermore,  the  relative 
levels of resistance observed with this method were surpris- 
ingly different from the results obtained with the cell growth 
assay (see Fig. 1 and Table II). For example, whereas mutant 
lines BFY-1, -7, and -9 display similar levels of resistance in 
the  growth assay (Table II), the  distribution  of Man II in 
BFY-7  and BFY-9 is completely sensitive to 5  /zg/ml BFA 
(Fig.  5, H  and K), but that in BFY-1 cells was resistant to 
BFA concentrations as high as 20 #g/ml (Fig. 5, E). A high 
level of resistance to BFA is not limited to the Golgi complex 
of BFY-1 cells. Indeed, Golgi morphology in three other cell 
lines (BFY-2, -3, and -12) remains normal at BFA concentra- 
tions as high as  10 #g/ml (data not shown).  The observed 
differences in the level of resistance of Golgi morphology to 
BFA among mutants most likely result from mutations at dif- 
ferent positions within a same gene, or in distinct genes. The 
lack of correlation between growth inhibition by BFA in mu- 
tant cells and the stability of Golgi morphology at high BFA 
concentration raises interesting questions about the mecha- 
nism of action of BFA which are addressed in more detail 
in the Discussion. 
Early Endosomes of BFY Cells Are Sensitive to BFA 
The effects of BFA are not limited to the Golgi apparatus. For 
example,  treatment with  BFA  causes  extensive tubulation 
and fusion of the early endosome and the TGN to form a hy- 
brid organelle (Lippincott et al.,  1991;  Tooze and Hollins- 
head, 1992; Wood and Brown,  1992). Limited tubulation of 
lysosomes also  results  from BFA  treatment  in  some cell 
types (Lippincott et al.,  1991; Wood et al.,  1991).  For this 
reason, we determined what effect, if any, BFA had on these 
organelles in several of our BFY lines. Treatment with BFA 
at concentrations as high as 10 pg/ml for 1 h had no visible 
effect on the distribution of the two lysosome markers lgp95 
and lgp58 (Joiner et al.,  1990;  van der Sluijs et al.,  1992) 
in the wild-type CHO line (data not shown). 
In contrast, a marked effect on the distribution of the early 
endosomes of wild-type CHO cells was observed upon treat- 
ment with 1 #g/m1 BFA (Fig. 6, a  and b). The clustering of 
the hybrid organelle resulting from the BFA-induced fusion 
of early endosomes with TGN has been best demonstrated 
using antibodies to TGN-38, a common marker of the TGN 
(Ladinsky  and  Howell,  1992).  Several  antibodies  raised 
against  rat  TGN-38  (generous  gifts  of  Dr.  K.  Howell, 
chase periods  (B). After the chase, cell lysates were immunoprecipitated  with a VSV-G antibody and one 
were then subjected to endo-H treatment,  as indicated.  The final results were visualized by SDS-PAGE. 
F/gure 7. Acquisition of endo-H 
resistance  is  not  affected by 
BFA treatment  in BFY-1 mu- 
tant cells.  VSV-infected cells 
were pulse labeled for 15 rain 
with [~SS]methionine and then 
chased for the indicated peri- 
ods of time with cold methio- 
nine. Half of the cell samples 
were preincubated  with 2 gg/ 
ml BFA for 30 rain before la- 
beling  and  BFA  levels  were 
maintained  during  pulse  and 
half of the immunocomplexes 
A fluorogram is shown. 
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CO) were tested, but none were found to cross-react with 
CHO cells. As an alternative, EE were labeled by endocyto- 
sis  of human transferrin,  a  marker used routinely for the 
identification of early endosomes (Hopkins, 1983; Hopkins 
and Trosbridge, 1983; Lippincott et al.,  1991).  The results 
shown in Fig. 6 demonstrate that the early endosome-TGN 
system of BFY-1 and BFY-12 cells have the same sensitivity 
to BFA displayed by the parent CHO wild-type cell line. This 
effect can be observed at a BFA concentration as low as 0.2 
#g/ml. In all six mutant lines examined (BFY-1, -2, -3,  -7, 
-12, and -21), BFA causes a clear redistribution of the endo- 
cytosed material to a perinuclear location under conditions 
where Golgi markers remain unaffected. This observation 
provides additional strong evidence for the presence of mul- 
tiple organdie-specific targets for BFA. Finally, the sensitiv- 
ity of EE/TGN of BFY mutant lines to low concentrations 
of BFA demonstrates that their BFA resistance cannot have 
arisen from the lack of import or increased export of  the drug 
by a multi drug transporter. 
Golgi Function Remains Normal in the Presence of 
BFA in BFY-1 Cells 
The experiments in Fig. 5 established that the appearance of 
the Golgi in BFY-1 cells is unaffected by high concentrations 
of BFA and therefore suggest that Golgi function remains 
normal in this line despite the presence of the drug. Prelimi- 
nary characterization of Golgi function in BFY-1 cells was 
performed by measuring total protein secretion from cells 
pulse labeled with [35S]methionine. The results demonstrated 
that whereas secretion from the parent wild-type CHO line 
was completely inhibited by 1 #g/ml BFA during a 60-min 
chase period, secretion from BFY-1 cells remained normal 
at that concentration (data not shown). Golgi function in this 
line was investigated in more detail by measuring the effect 
of BFA on Golgi-dependent protein glycosylation in both 
mutant and wild-type cells, using resistance to endo-H as an 
assay. The loss of  endo-H sensitivity indicates the conversion 
of asparagine-linked oligosaccharides from a high mannose 
to a  complex form which occurs within the medial Golgi 
compartment. 
In the experiment shown in Fig. 7, VSV-infected cells were 
pulse labeled with ['S]methionine, and then chased for the 
indicated periods of time with cold methionine. As a control 
for the experiment, Fig. 7 A shows that the endo-H-sensitive 
forms of the VSV-G protein observed after the brief pulse 
were fully converted to endo-H-resistant forms during the 
60-min chase in both wild-type and BFY-1 cells, in the ab- 
sence of BFA. In contrast, a significant difference between 
wild-type and mutant cells was observed when ceils were 
treated with 2/zg/ml BFA (Fig. 7, B). In wild-type CHO cells 
VSV-G was only partially resistant to endo-H after a 60-rain 
chase, as previously reported (Doms et al., 1989). The partial 
processing of VSV-G most likely results from redistribution 
of  Golgi enzymes to the ER (Doms et al., 1989). In contrast, 
the VSV-G protein made in mutant BFY-1 cells  acquired 
endo-H resistance with kinetics similar to those observed in 
untreated cells. The abnormal migration of the VSV-G pro- 
duced in BFY-1 cells in the presence of BFA could result 
from increased sialylation due to disruption of the endosome- 
TGN system (see Fig 6). We conclude that BFA causes a de- 
lay in the conversion of newly synthesized asparagine-linked 
oligosaccharides from high mannose to complex forms in 
wild-type cells but has no such effect in mutant BFY-1 cells. 
The observation that the Golgi complex not only appears 
normal but also functions properly at a BFA concentration 
sufficient to inhibit growth (see Fig.  1) reveals a novel effect 
of BFA which is independent of its ability to disrupt organelle 
morphology. 
Resistance to BFA in BFY-1 Cells Involves a 
Membrane-associated Factor Distinct from ARFs 
and Coatomers 
One of the most immediate effects of BFA in wild-type cells 
is to interfere with assembly of protein coats on Golgi mem- 
branes (Klausner et al.,  1992).  This effect of BFA can be 
readily monitored as displacement of the ll0-kD coat pro- 
tein/3-COP from Golgi membranes (Lipincott-Schwarz et 
al.,  1989).  Preliminary  experiments  using  indirect  im- 
munofluorescence established that the membrane associa- 
tion of/3-COP in BFY-1 cells was unaffected by BFA, even 
in  semi-intact cells  incubated with  BFA-sensitive cytosol 
(data not shown). These results suggested that resistance to 
BFA resulted from a membrane-associated factor retained in 
the permeabilized cells. This possibility was investigated by 
preparing Golgi-enriched membrane fractions from either 
wild-type or mutant cells and determining their relative sen- 
sitivity to BFA using a cell-free assay that measures mem- 
brane association of coat proteins in the absence or presence 
of BFA (Fig.  8).  In these assays,  soluble components re- 
quired for coat assembly were provided by cytosol prepared 
from BFA-sensitive CHO lecl cells. We found that the extent 
of/3-COP binding to wild-type and BFY-1 membranes in the 
absence of BFA was similar and corresponded to '~25 % of 
the total amount of/3-COP present in the reaction. As shown 
in Fig. 8, association of/3-COP-containing coatomers with 
wild-type Golgi membranes was inhibited by BFA in a dose- 
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Figure 8. A BFA resistance factor is associated with Golgi mem- 
branes. Golgi-enriched membranes prepared either from wild-type 
(0) or from mutant  BFY-1 (o) cells were incubated with cyto- 
sol prepared from BFA-sensitive CHO lecl cells in the presence 
of the indicated BFA concentrations for 20 rain at 30°C. The extent 
of B-COP associated with membranes at the end of the incubation 
was determined as described in Materials and Methods and is plot- 
ted as a function of BFA concentration. A phosphorImager print 
and a fluorogram are shown. 
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with BFY-1 membranes was fully resistant to BFA. This ob- 
servation  demonstrates  that  the  BFA  resistance  factor  in 
BFY-1 cells is indeed membrane associated.  Furthermore, 
the fact that similar amounts of/~-COP bound to wild-type 
and BFY membranes suggests that resistance in BFY-1 cells 
does not result from a  large increase in the affinity of co- 
atomers for Golgi membranes. 
Could ARFs or COPs be directly involved in the mecha- 
nism of resistance to BFA in BFY-1 cells? The observation 
that  a  BFA  resistance  factor is  associated  with the  Golgi 
membranes of these cells makes this unlikely,  since ARFs 
and COPs normally dissociate from membranes during iso- 
lation. Examination of the relative levels of ARF and/S-COP 
in cell extracts verifies that wild-type and mutant membranes 
indeed carry equally low amounts of these coat proteins (Fig. 
9). Quantitative analysis reveals that <10% of COPs in these 
binding  assays are provided by membranes.  Furthermore, 
the levels of ARF and coatomer in cytosol prepared from 
wild-type and mutant cells are also very similar (Fig.  9). 
This is in agreement with our observation that the levels of 
these proteins in total extracts of BFY-1 and BFY-12 cells are 
within experimental error (4-5 %) of those measured in wild- 
type cells.  These results strongly suggest that resistance in 
these BFY lines does not result from mutations in ARFs or 
coatomers, or from changes in their expression level. 
Discussion 
The effects of the small fungal metabolite BFA on organelle 
morphology and function are dramatic: membranes tubulate 
and fuse into several separate subsystems from which pro- 
tein  exit is  in  some cases  significantly altered.  Much has 
been learned on the effects of BFA on several organelles and 
in a  wide variety of cell types. However, the exact mecha- 
nism of action of BFA remains to be elucidated. 
In this study, several CHO mutant cell lines (termed BFY) 
were isolated from EMS-mutagenized populations on the ba- 
sis of their ability to grow in the presence of 1 #g/ml BFA. 
Extensive characterization of a subset of these mutant lines 
has established that most lines are genetically stable,  and 
that  BFA  resistance does  not  result  from trivial changes, 
such as enhanced  inactivation by covalent modification or 
rapid efflux by a multidrug transporter. In addition, all mu- 
tant  lines  characterized  were  found  to  display  organelle- 
specific resistance. Cell-free measurements with membrane 
extracts establish that resistance to BFA in BFY-1 cells in- 
volves a membrane-associated factor distinct from ARFs and 
coatomers. We conclude from these observations that resis- 
tance in these cells most likely arose from changes in the 
function of either an organelle-specific cellular target(s) for 
BFA or of a protein that interact with such a  target(s). 
Organelle-specific resistance to BFA has been reported in 
the two naturally resistant lines PtK-1 and MDCK (Hunziker 
et  al.,  1991;  Ktistakis  et  al.,  1991;  Low  et  al.,  1992; 
Apodaca et al.,  1993).  However, the relative effects of BFA 
on cell growth and organelle distribution in these lines were 
not investigated. The usefulness of these cell fines in iden- 
tifying a cellular target(s) for BFA is further limited by the 
fact that resistance could have arisen over time from changes 
in  several  genes.  Previous  selections  from  mutagenized 
populations of Vero (Chen et al.,  1992)  and human carci- 
noma cells (Seguchi et al., 1992) have yielded three cell lines 
that can grow in presence of BFA. In all three cases, charac- 
terization revealed changes associated with the Golgi com- 
plex.  However, the  small  number of mutants  obtained  in 
these  studies  and the  lack of measurements on organelles 
other than the Golgi complex did not allow any generaliza- 
tions  about the  mechanism of resistance  to  BFA.  As  de- 
scribed  below,  the  collection  and  characterization  of our 
CHO  BrY  lines  overcomes  these  limitations  and  provides 
several novel insights. 
Figure 9. BFA resistance does not arise from changes in the level 
or membrane association  of ARFs  and  /S-COP. Golgi-enriched 
membrane  fractions  (m)  and  cytosol  (c)  prepared  from either 
pro  -5, BFY-1, or BFY-12 cells were subjected to SDS-PAGE. The 
amounts of membrane (2.5 #g) and cytosol (22.5 #g) loaded cor- 
respond  to the ratios  present  in a COP-binding assay. Following 
transfer  to  nitrocellulose,  blots  were  incubated  with  a  E-COP 
specific antibody (m3A5) or [c~-32P]GTP  to determine the relative 
levels  of COPs  and  ARFs  in  those  samples,  as  described  in 
Materials and Methods. Quantitation of such blots establishes that 
greater than 90 % of COPs and ARFs in all COP-binding assays are 
provided by cytosol. 
Figure 10.  Two models for organelle-specific resistance to BFA in 
BFY lines.  (A) EE and Golgi complex have distinct BFA targets. 
Mutation  in the Golgi specific target can lead to BFA resistance. 
(B) A single BFA target acts on distinct organelle-specific effectors. 
Mutations  in either the BFA target or Golgi-specific effector can 
lead to BFA resistance.  If the mutation occurs in the BFA target, 
both EE and Golgi will be BFA resistant. In this model, the effector 
mutation could alter either the activity or the concentration of the 
effector in an organelle-specific manner. 
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OrganeUe-specific Proteins 
Three separate selections yielded BFA-resistant mutants of 
CHO  cells  at a  frequency of 2-30  per  107  mutagenized 
cells. The observation of such a high frequency in three sepa- 
rate  attempts  suggests  that mutation of a  single  gene  is 
sufficient to yield a  BFA-resistance phenotype. Does this 
demonstrate that BFA has a single target in CHO cells? As 
discussed below,  several of our observations indicate that 
this is not the case. 
First, mutations conferring BFA-resistance in BFY cells 
do not eliminate all effects of BFA, but rather are organelle 
specific. Indeed, whereas the morphology of the Golgi com- 
plex in all BFY lines tested is completely unaffected by a 1-h 
treatment with  1 #g/ml BFA  (or even 20 /xg/ml in BFY-1 
cells), the early endosomes in all six of the mutant lines 
characterized are disrupted by BFA in a manner identical to 
that observed in wild-type cells. It is particularly significant 
that the BFA sensitivities of these two organelles are nearly 
identical in the parent wild-type ceils, but show large and 
varied differences in BFY lines. This dramatic change in the 
relative BFA sensitivities of the Golgi and early endosomes 
upon mutation in BFY cells can be best explained by the pres- 
ence of multiple organelle-specific targets for BFA (Fig. 10, 
A), or by the presence of multiple organdie-specific "effec- 
tors" for the activity of a unique BFA target (Fig.  10, B). 
Model B predicts that some BFY lines could be obtained by 
mutation of the BFA target resulting in BFA resistance of  both 
Golgi and endosomes. The availability of a large collection 
of  mutant lines will allow a partial test of  this prediction. Our 
observation to date that none of the six characterized BFY 
mutants show BFA resistance in both organelles favors A. 
Second, whereas the growth of all BFY lines is clearly 
resistant to BFA relative to the wild-type parent line, none 
of those characterized grow above a BFA concentration of 
2/~g/ml. In BFY-1 cells, this growth inhibition is not due to 
nonspecific effects such as disruption of the lipid bilayer by 
BFA (Zizi et al.,  1991),  since the inactive BFA analogues 
B27 and B36 cause no growth inhibition at concentrations as 
high as 3 #g/ml. This growth inhibition is not likely to result 
from known effects on organelles either, since Golgi function 
appears normal at BFA concentration as high as 2/zg/ml in 
BFY-1 cells. Rather, inhibition could result from the pres- 
ence of an additional cellular target(s)  for BFA  which is 
affected only at high concentration and is not mutated in 
BFY cells. Elucidation of the mechanism causing growth in- 
hibition in mutant cells may provide important new insights. 
If BFA has multiple targets, how can BFA-resistant cells 
be obtained at such high frequency? Cell survival under our 
selection  conditions  require  mutation  only  in  target(s) 
significantly affected at 1 /xg/ml BFA, and whose function 
was also essential. Our observation that all BFY lines tested 
have  resistant  Golgi  morphology suggests  that an  intact 
Golgi complex is required for growth. In contrast, mutations 
leading to BFA-resistant endosomes were apparently not re- 
quired. This can be in part explained by the fact that BFA 
do~,s not block endocytosis (Lippincott et al.,  1991; Wood 
and Brown, 1992). Furthermore, the ligand uptake and sort- 
ing carded out by the endosome-TGN system, which can be 
affected by BFA (Lippincott et al., 1991), may not be essen- 
tial for growth under tissue culture conditions (Robbins  et 
al.,  1983;  Klausner et al.,  1984). 
Identification of the Cellular Target(s)for BFA 
Comparison of the effect of BFA on growth or the morphol- 
ogy of the Golgi complex in several BFY cells revealed ex- 
tensive variation.  Several  explanations could account for 
these phenotypic variations. Mutations may have occurred at 
different  positions within the same gene thereby reducing the 
affinity for the drug to different extents, or the level of ex- 
pression of the wild-type or mutated BFA target could have 
been increased to different extents in the various mutant 
lines.  Alternatively, future complementation analysis may 
show that mutations have been obtained in several different 
genes. Elucidation of  the mechanism of resistance in the var- 
ious lines could therefore lead not only to the identification 
of cellular targets for BFA, but also of proteins interacting 
with these targets. A whole cascade involved in regulating 
assembly of organelle-specific coats may thus be revealed. 
Many biochemical assays can now be used to investigate 
the mechanism of resistance in BFY cells and identify com- 
ponents of this cascade. We have established that resistance 
to BFA in BFY-1 cells involves a membrane-associated factor 
which is distinct from ARFs and COPs. We conclude that 
resistance in these cells did not arise by overexpression of 
these downstream effectors of BFA, but more likely by muta- 
tion of  the BFA target itself. For example, mutation may have 
occurred in the enzyme directly responsible for activation of 
ARFs by guanine nucleotide exchange, or in proteins regu- 
lating this exchange activity. Future measurements of the 
BFA effect on the ability of mutant Golgi-membranes to stim- 
ulate GTP-binding by ARFs (Donaldson et al., 1992; Helms 
and Rothman, 1992) will address these issues. In addition, 
since our results strongly suggest that resistance to BFA in 
BFY cells arose from a single mutation, cDNA expression 
cloning from BFY mutant libraries provides another very 
promising avenue for the identification of BFA target(s). 
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